These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 12510413

  • 1. [Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy].
    Bettini R, Gorini M.
    Clin Ter; 2002; 153(5):305-7. PubMed ID: 12510413
    [Abstract] [Full Text] [Related]

  • 2. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD.
    Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
    [Abstract] [Full Text] [Related]

  • 3. Clinical studies with silymarin: fibrosis progression is the end point.
    Schuppan D, Hahn EG.
    Hepatology; 2001 Feb; 33(2):483-4. PubMed ID: 11172360
    [No Abstract] [Full Text] [Related]

  • 4. [Efficacy of ursodeoxycholic acid (UDCA) in the treatment of chronic alcoholic hepatitis].
    Preobrazhenskiĭ VN, Taianovskiĭ VIu.
    Klin Med (Mosk); 1998 Feb; 76(5):26-8. PubMed ID: 9644931
    [Abstract] [Full Text] [Related]

  • 5. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR, Attia M, Badran HM, El-Tawil A, Zalata K, Barakat E, Selim O, El-Nakeeb A, Saied A.
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [Abstract] [Full Text] [Related]

  • 6. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
    Avezov SA, Mansurova FKh.
    Klin Med (Mosk); 2004 Aug; 82(2):46-9. PubMed ID: 15106512
    [Abstract] [Full Text] [Related]

  • 7. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalçin S, Akan H.
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [Abstract] [Full Text] [Related]

  • 8. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S, Masaki T, Tanaka K.
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
    Avezov SA, Mansurov FKh.
    Klin Med (Mosk); 2004 Jan; 82(3):55-8. PubMed ID: 15114777
    [Abstract] [Full Text] [Related]

  • 10. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R.
    J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
    [Abstract] [Full Text] [Related]

  • 11. [Positive effect of ursodeoxycholic acid on liver enzymes in autoimmune hepatitis with little activity--a pilot study].
    Janowitz P, Kratzer W, Wechsler JG.
    Leber Magen Darm; 1996 Nov; 26(6):310-3. PubMed ID: 9082112
    [Abstract] [Full Text] [Related]

  • 12. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease.
    Lirussi F, Okolicsanyi L.
    Acta Physiol Hung; 1992 Nov; 80(1-4):363-7. PubMed ID: 1345202
    [Abstract] [Full Text] [Related]

  • 13. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy.
    Binder T, Salaj P, Zima T, Vítek L.
    J Perinat Med; 2006 Nov; 34(5):383-91. PubMed ID: 16965225
    [Abstract] [Full Text] [Related]

  • 14. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A, Swiss Association for the Study of the Liver.
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [Abstract] [Full Text] [Related]

  • 15. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH.
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients].
    Trinchet JC, Coste T, Lévy VG, Vivet F, Duchatelle V, Legendre C, Gotheil C, Beaugrand M.
    Gastroenterol Clin Biol; 1989 Sep; 13(2):120-4. PubMed ID: 2707520
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM, Kaplan MM.
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [Abstract] [Full Text] [Related]

  • 18. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA, Sanai FM, Swain MG.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):813-20. PubMed ID: 16918885
    [Abstract] [Full Text] [Related]

  • 19. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
    Assy N, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN.
    Transplantation; 2007 Jun 27; 83(12):1571-6. PubMed ID: 17589339
    [Abstract] [Full Text] [Related]

  • 20. The effects of ursodeoxycholic acid alone and ursodeoxycholic acid plus low-dose acetylsalicylic acid on radiolucent gallstones.
    Tuncer I, Harman M, Mercan R, Oztürk M, Arslan I, Meral C, Türkdoğan MK.
    Turk J Gastroenterol; 2003 Jun 27; 14(2):91-6. PubMed ID: 14614633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.